Generic name
Desmopressin: adverse event reports filed with FDA
1,555 reports list it as a suspect or interacting product, 2004–2026. Also reported as Desmopressin 0 2mg.
- 1,555
- reports as suspect product
- 0% of all reports · about 70 a year
- 109
- reports, 12 months to June 2026
- 135 in the 12 months before
- 75.4%
- marked serious by the reporter
- 57.4% across all reports
- 5.7%
- record death among outcomes, as reported
- 88 reports · not verified by FDA
Between April 2004 and June 2026, 1,555 adverse event reports received by FDA list desmopressin, a generic name as a suspect or interacting product. Reports that mention it only as a concomitant medication (2,827) are left out of every figure here.
In the 12 months to June 2026, 109 reports listed it, down 19% from 135 in the 12 months before. FDA releases FAERS data quarterly, so the newest months are incomplete and grow in later releases. Over its reporting history that is about 70 reports a year and 0% of the 20,646,523 reports in the database. How many people take it is not in the data, so a count is not a rate of occurrence.
Reporters most often recorded hyponatraemia (23.3%), drug ineffective (12.8%) and off label use (7%). A report can list several reactions, so shares add to more than 100%; 408 different terms appear across these reports. Hyponatraemia is recorded in 23.3% of these reports, against 0.3% of all reports in the database.
75.4% of the reports are marked serious by the reporter; 5.7% record death among the outcomes and 41.7% record hospitalisation, as reported. 39.5% of the reports came from other health professionals, and the largest patient age group is 18 to 44 (19%). FDA states that "a causal relationship cannot be established between product and reactions listed in a report" and that for any given report "there is no certainty that a suspected drug caused the event."
Reports by month, five years
Reports by the month FDA received them. FDA releases FAERS data quarterly, so the newest months are incomplete and grow in later releases.
By year received
2026 covers reports received through June 2026 only.
Reactions recorded in the reports
share of Desmopressin reports recording the termall reports in the database
- Hyponatraemialow blood sodium23.3%363
- Drug ineffectivethe medicine did not work as expected12.8%199
- Off label useused for a purpose or in a way not on the label7%109
- Drug interactionan interaction between medicines6.3%98
- Product storage errorthe product was stored wrongly6.2%96
- Seizurea fit or convulsion4.8%75
- Product use in unapproved indicationused for a purpose not on the label4.4%68
- Headachehead pain4%62
- Foetal exposure during pregnancythe unborn baby was exposed to the medicine3.7%58
- Vomitingbeing sick3.5%54
- Blood sodium decreased3.1%48
- Nauseafeeling sick2.8%44
- Maternal exposure during pregnancythe mother took the medicine during pregnancy2.7%42
- Hypernatraemia2.6%40
- Pollakiuriapassing urine more often2.6%40
- Premature babya baby born early2.6%40
- Exposure during pregnancythe medicine was taken during pregnancy2.4%37
- Dizzinesslight-headedness or unsteadiness2.3%35
- Malaisegeneral feeling of being unwell2.1%32
- Urinary retentionbeing unable to empty the bladder2.1%32
- Falla fall2%31
- Overdosea dose above the recommended amount2%31
- Astheniaweakness or lack of energy1.9%29
- Fatiguetiredness1.8%28
- Confusional stateconfusion1.7%26
- Urinary tract infectionbladder or urinary infection1.6%25
- Oedema peripheralswelling of the legs, ankles or hands1.5%24
- Somnolencedrowsiness1.5%24
- Condition aggravatedthe condition being treated got worse1.5%23
Top 30 of 408 MedDRA preferred terms recorded across these reports, with a plain-language gloss where one is available. One report can record several terms. The hollow bar is the share of all reports in the database; it describes the reports, not the patients. FDA states that adverse event reports "represent a small percentage of total usage numbers of a product", that "common products may have a higher number of adverse events due to the higher total number of people using the product", and that the data "by themselves are not an indicator of the safety profile of the drug or biologic."
Outcomes recorded
Outcome flags as the reporter set them; a report can carry several, and "other serious" is FDA's own category for serious reports outside the named outcomes. Grey bar: all 20,646,523 reports. FDA has not verified any outcome and states that the reports "cannot be used to estimate the incidence of these events."
Patients and reporters
Patient age
Patient sex
Who reported
Age and sex as stated in the report; the reporter's qualification is the primary source recorded by FDA. 49.5% of reports give the United States as the country of the event or reporter.
Reason for use recorded
| Indication as recorded (MedDRA) | Reports | Share |
|---|---|---|
| Diabetes insipidus | 371 | 23.9% |
| Enuresis | 79 | 5.1% |
| Nocturia | 59 | 3.8% |
| Urinary incontinence | 30 | 1.9% |
| Von willebrand's disease | 26 | 1.7% |
| Hypopituitarism | 24 | 1.5% |
The indication field is filled in by the reporter and is often blank; shares are of all 1,555 reports.
Drugs most often listed in the same reports
| Drug (any role in the report) | Reports | Share of Desmopressin reports |
|---|---|---|
| Hydrocortisone | 159 | 10.2% |
| Levothyroxine | 125 | 8% |
| Levetiracetam | 67 | 4.3% |
| Norepinephrine | 57 | 3.7% |
| Lorazepam | 56 | 3.6% |
| Lamotrigine | 54 | 3.5% |
| Atorvastatin | 44 | 2.8% |
| Gabapentin | 42 | 2.7% |
| Sodium chloride | 42 | 2.7% |
| Propofol | 38 | 2.4% |
Other products listed in reports where Desmopressin is a suspect product, whatever their own role. Co-listing means the two were recorded together; it says nothing about either product's part in the event. Only the 2,500 most-reported names are counted here.
In context
| Measure | Desmopressin | All reports |
|---|---|---|
| Reports as suspect product | 1,555 | 20,646,523 |
| Share of that pool | — | 0% |
| Reports, latest 12 months | 109 | 1,332,454 |
| Marked serious | 75.4% | 57.4% |
| Death recorded among outcomes, per 1,000 reports | 57 | 91 |
| Hospitalisation recorded, per 1,000 reports | 417 | 213 |
| Consumer-filed share | 23.5% | 45.8% |
| Top term, share of reports | Hyponatraemia 23.3% | 0.3% |
Shares are of reports, not of patients treated. The number of people taking a product is not in the data, so none of these figures is a rate, and differences between columns reflect who takes a product, who reports and how long it has been sold. FDA states that adverse event reports "represent a small percentage of total usage numbers of a product", that "common products may have a higher number of adverse events due to the higher total number of people using the product", and that the data "by themselves are not an indicator of the safety profile of the drug or biologic."
Questions about Desmopressin reports
How many adverse event reports has FDA received for Desmopressin?
1,555 reports list Desmopressin as a suspect or interacting product in the openFDA FAERS release of 28 Sep 2026, covering reports received through June 2026. 109 of them arrived in the latest 12 months. Another 2,827 list it only as a concomitant medication.
What reactions are recorded in Desmopressin reports?
hyponatraemia (23.3%), drug ineffective (12.8%), off label use (7%), drug interaction (6.3%) and product storage error (6.2%). These are MedDRA preferred terms coded from what the reporter described; a report can list several, and a term's presence is not a finding that Desmopressin was responsible.
How serious are the reports?
75.4% are marked serious by the reporter. Among the outcomes recorded, 5.7% of reports include death and 41.7% include hospitalisation. FDA has not verified these outcomes and states that the reports "cannot be used to estimate the incidence" of the events.
Who files these reports?
other health professional (39.5%), consumer or non-health professional (23.5%) and physician (20.6%). Most reports reach FDA through the manufacturer, which must forward reports it receives.
Are reports for Desmopressin rising?
109 reports in the 12 months to June 2026, down 19% from 135 in the 12 months before. FDA releases FAERS data quarterly, so the newest months are incomplete and grow in later releases. Counts also move with how many people take a product, its time on the market and publicity.
Do these reports show that Desmopressin was responsible for these reactions?
No. FDA states that "a causal relationship cannot be established between product and reactions listed in a report" and that for any given report "there is no certainty that a suspected drug caused the event." The reaction may relate to the condition being treated, to other medicines, or to something else.
Is this a list of the side effects of Desmopressin?
No. It is a count of what was reported to FDA. The adverse reactions observed in clinical studies are printed on the FDA-approved label, which a pharmacist or clinician can go through with you.
How do I report an adverse event?
Consumers and health professionals can report to FDA through MedWatch (Form FDA 3500 online, or 1-800-FDA-1088), or to the manufacturer, which must pass reports on. See the guide on how to report.
Where this comes from. Counts are built from the openFDA Drug Adverse Event (FAERS) bulk export released 28 Sep 2026, which holds reports FDA received through 30 Jun 2026. Drug names are as reported, resolved to the brand or generic name on the FDA label where openFDA's harmonisation matched them; classes are the pharmacologic class (EPC) from the label and the National Drug Code Directory of 17 Sep 2026. A report counts here when it lists Desmopressin as a suspect or interacting product; reports listing it only as a concomitant medication (2,827) are excluded. No report narrative, lot number, patient detail or reporter identity is published. See the methodology and sources; FDA's record is authoritative, and corrections are handled within five working days.
Drug data (FAERS) through 30 Jun 2026; device data (MAUDE) through 31 Aug 2026. Not medical advice.